Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

AZN

Astrazeneca plc

Feb 13 • 01:42PM ET

204.70

+0.18 0.09 %

Healthcare • Drug Manufacturers - General • United Kingdom • NYSE

Held by: PVAL AVDE DIHP DFIC PPH FVD DFAX PLDR APIE JDVL

Scroll to Statements

Index	-	P/E	31.25	EPS (ttm)	6.55	Insider Own	4.81%	Shs Outstand	1.55B	Perf Week	6.04%
Market Cap	317.38B	Forward P/E	17.76	EPS next Y	11.52	Insider Trans	0.00%	Shs Float	1.48B	Perf Month	7.61%
Enterprise Value	341.31B	PEG	1.50	EPS next Q	2.50	Inst Own	53.77%	Short Float	0.26%	Perf Quarter	16.53%
Income	10.22B	P/S	5.40	EPS this Y	11.99%	Inst Trans	-2.58%	Short Ratio	7.95	Perf Half Y	31.43%
Sales	58.74B	P/B	6.92	EPS next Y	12.33%	ROA	9.38%	Short Interest	3.88M	Perf YTD	16.64%
Book/sh	29.60	P/C	55.28	EPS next 5Y	11.86%	ROE	22.86%	52W High	205.86 -0.56%	Perf Year	37.44%
Cash/sh	3.70	P/FCF	26.10	EPS past 3/5Y	45.90% 22.05%	ROIC	13.67%	52W Low	122.26 67.43%	Perf 3Y	46.97%
Dividend Est.	3.42 (1.67%)	EV/EBITDA	17.65	Sales past 3/5Y	9.82% 16.31%	Gross Margin	74.35%	Volatility	2.69% 3.01%	Perf 5Y	98.77%
Dividend TTM	3.16 (1.54%)	EV/Sales	5.81	EPS Y/Y TTM	45.27%	Oper. Margin	23.16%	ATR (14)	6.51	Perf 10Y	247.54%
Dividend Ex-Date	Feb 20, 2026	Quick Ratio	0.72	Sales Y/Y TTM	8.63%	Profit Margin	17.41%	RSI (14)	65.26	Recom	1.70
Dividend Gr. 3/5Y	1.78% 3.25%	Current Ratio	0.94	EPS Q/Q	54.97%	SMA20	8.67%	Beta	0.37	Target Price	215.60
Payout	47.19%	Debt/Eq	0.61	Sales Q/Q	4.11%	SMA50	10.24%	Rel Volume	4.40	Prev Close	204.52
Employees	94300	LT Debt/Eq	0.54	Earnings	Feb 10 BMO	SMA200	27.81%	Avg Volume	488.48K	Price	204.70
IPO	Oct 17, 2003	Option/Short	Yes / Yes	EPS/Sales Surpr.	1.32% 0.38%	Trades		Volume	1,426,284	Change	0.09%

Today 10:45AM	Shore Capital downgrades AstraZeneca as R&D spending dampens earnings trajectory (Proactive)
07:00AM	Positive and clinically meaningful results from the Phase III KALOS and LOGOS trials for BREZTRI in patients with uncontrolled asthma published in The Lancet Respiratory Medicine (Business Wire)
Feb-12-26 01:26PM	A Closer Look at Healthcare Sector Earnings: AZN vs. EW vs. ZBH (MarketBeat)
10:35AM	IRWD Rises 307% in 6 Months: Is This an Indication to Buy the Stock? (Zacks)
09:13AM	Here's What Lifted AstraZeneca PLC (AZN) in Q4 (Insider Monkey)
07:55AM	Loading…
07:55AM	Upstream Bios stock drops 47% on verekitug Phase II asthma data (Clinical Trials Arena)
04:36AM	Sanofi says board has removed CEO Paul Hudson (AFP)
Feb-11-26 08:04PM	AstraZeneca PLC (AZN) Q4 2025 Earnings Call Highlights: Strong Revenue Growth and Strategic ... (GuruFocus.com) +5.87%
02:23PM	NIH Stops Johnson & Johnson's Blood Thinner Drug Arm In Stroke Trial After Safety Review (Benzinga)
10:45AM	Citi maintains 'buy' on AstraZeneca with £170 target, cites sector-best pipeline (Proactive)
09:00AM	AstraZeneca awards $3.4 million for programs to improve access to healthcare for patients across the US (Business Wire)
08:09AM	Can Pfizer's New & Acquired Drugs Offset Its Looming Patent Cliff? (Zacks)
06:44AM	Moderna shares fall as FDA declines to review new flu vaccine (Reuters)
04:33AM	Evommune rockets on eczema data; AstraZeneca advances GLP-1 pill (BioPharma Dive)
Feb-10-26 04:10PM	AstraZeneca Reiterates $80 Billion 2030 View Ahead Of 'Catalyst-Rich 2026' (Investor's Business Daily)
03:49PM	Loading…
03:49PM	AstraZeneca Q4 Earnings Call Highlights (MarketBeat)
12:32PM	AstraZeneca Cancer Portfolio Dominates Sales With Massive Double Digit Growth (Benzinga)
12:02PM	AstraZeneca bets on continued oncology demand for 2026 growth (Pharmaceutical Technology)
11:27AM	AstraZeneca to advance in-licensed oral GLP-1RA to pivotal trials (Clinical Trials Arena)
10:59AM	Jim Cramer on AstraZeneca: "We Want Every Drug Stock" (Insider Monkey)
09:42AM	AZN Q4 Earnings Miss Estimates, Stock Up on Robust 2026 Growth Outlook (Zacks)
09:41AM	BP, Ferrari, TSMC: Global Earnings in Focus (The Wall Street Journal)
09:30AM	Here's What Key Metrics Tell Us About Astrazeneca (AZN) Q4 Earnings (Zacks)
09:09AM	AstraZeneca Leans On Its Cancer Division For A Fourth-Quarter Beat (Investor's Business Daily)
08:30AM	Novel Serotonergic Agonists Positioned to Capture Share of $150B+ Neuropsychiatric Market (PR Newswire)
08:18AM	Ferrari, BP, TSMC: Global Earnings in Focus (The Wall Street Journal)
07:41AM	BP, Ferrari, TSMC: Earnings and Sales Globally in Focus (The Wall Street Journal)
07:00AM	AstraZeneca results: FY and Q4 2025 (Business Wire)
06:45AM	AstraZenecas growth engine stays on track despite cost pressures (Proactive)
06:33AM	AstraZeneca Reiterates $80 Billion Revenue Goal for 2030 (The Wall Street Journal)
06:22AM	Loading…
06:22AM	AstraZeneca profit jumps as cancer drug sales grow (AFP)
06:18AM	Stocks mostly rise tracking tech, earnings (AFP)
05:27AM	BP, Kering, Barclays: Earnings Around the World in Focus (The Wall Street Journal)
05:27AM	BP, Barclays, TSMC: Global Earnings and Sales in Focus (The Wall Street Journal)
03:06AM	AstraZeneca forecasts 2026 sales, profit growth as Q4 meets expectations; stock up (Investing.com)
02:35AM	Astrazeneca: Q4 Earnings Snapshot (Associated Press Finance)
02:34AM	AstraZeneca Forecasts Continued Growth on Pipeline Strength (The Wall Street Journal)
02:24AM	AstraZeneca profit climbs on cancer and heart drug demand (MarketWatch)
02:08AM	AstraZeneca lifts earnings as pipeline delivery and global expansion underpin growth (Proactive)
Feb-09-26 07:00PM	Robinhood earnings, Fed comments, retail sales: What to Watch (Yahoo Finance Video)
11:38AM	Will These 5 Drug Bigwigs Surpass Q4 Earnings Forecasts? (Zacks)
10:44AM	Dow Jones retreat from highs as Amazon and Apple fall (Proactive)
09:39AM	Week ahead: Markets to test rebound with earnings, jobs data due (Proactive)
09:24AM	J&J Posts Innovative Medicine Growth in 2025 Amid Stelara Patent Loss (Zacks)
09:11AM	Should You Buy, Sell or Hold Pfizer Stock After a Lukewarm Q4? (Zacks)
07:16AM	AstraZeneca PLC (LSE:AZN) Q4 2025 Earnings Report Preview: What To Expect (GuruFocus.com)
02:30AM	Jobs Report, CPI Data: What to Watch This Week (The Wall Street Journal)
Feb-06-26 07:00PM	Super Bowl LX, Coinbase earnings, jobs data & CPI: What to Watch (Yahoo Finance Video)
06:45PM	Jobs Report, CPI Data: What to Watch Next Week (The Wall Street Journal)
05:13PM	TrumpRx Is Here. Most People Wont Benefit. (Barrons.com)
11:58AM	TrumpRx launches to slash drug prices for cash-paying US patients (Pharmaceutical Technology)
08:00AM	China Biotech Lights Up. U.S. Stocks Prepare For A New Powerhouse. (Investor's Business Daily)
07:08AM	White Houses online service for drug sales debuts with limited impact on prices (BioPharma Dive)
06:30AM	Broker initiates coverage of Capita with a 'buy' call (Proactive)
12:13AM	Trump Says People Will 'Save A Lot Of Money And Be Healthy' With Launch Of TrumpRx Website - But Will It Actually Fill Prescriptions? (Benzinga)
Feb-05-26 09:17PM	Trump launches TrumpRX website offering discounted prescription drugs (Investing.com)
09:15AM	Countdown to Astrazeneca (AZN) Q4 Earnings: A Look at Estimates Beyond Revenue and EPS (Zacks)
08:48AM	Does Ironwood's Bullish 2026 View Signal Greater Linzess Adoption? (Zacks)
08:31AM	AstraZeneca to Report Q4 Earnings: What's in Store for the Stock? (Zacks)
Feb-04-26 12:30PM	Shell chief exec to become one of FTSEs best paid bosses (The Telegraph)
12:29PM	Health Care Roundup: Market Talk (The Wall Street Journal)
10:19AM	AMGN's Q4 Earnings & Sales Beat Estimates, Obesity Candidate in Focus (Zacks)
10:11AM	FDA Rejects AZN's Saphnelo SubQ Formulation, Priority Tag to Datroway (Zacks)
Feb-03-26 06:15PM	Why Astrazeneca (AZN) Dipped More Than Broader Market Today (Zacks)
02:30PM	AstraZeneca Stock Soared 103% Monday, Holding At High Level. Gets Rating Upgrade. (Investor's Business Daily)
11:48AM	FDA Rejects AstraZeneca's Saphnelo Injection, Shares Drop 1.9% (GuruFocus.com)
11:36AM	MRK Q4 Earnings & Sales Beat Estimates, Stock Down on Weak '26 View (Zacks)
11:34AM	Jim Cramer Says "I Like AstraZeneca Very Much" (Insider Monkey)
11:02AM	Walmart hits $1 trillion market cap, joins tech giants (Investing.com)
07:00AM	DATROWAY (datopotamab deruxtecan-dlnk) granted Priority Review in the US as 1st-line treatment for patients with metastatic triple-negative breast cancer who are not candidates for immunotherapy (Business Wire)
06:55AM	AstraZeneca Responds With Data After FDA Delays Lupus Drug Shot (Benzinga)
05:11AM	FDA launches PreCheck program; AstraZeneca, Acadia drugs set back (BioPharma Dive)
04:34AM	AstraZeneca PLC (NASDAQ:AZN) Announces Strategic Collaboration Agreement With CSPC Pharmaceuticals (Insider Monkey)
02:42AM	AstraZenecas Initial Application for Lupus Injection Turned Down by FDA (The Wall Street Journal)
Feb-02-26 02:15PM	Should You Buy the Dip in IonQ Stock? (Barchart)
02:04PM	US and India reach trade deal, Astrazeneca shares move to NYSE (Yahoo Finance Video)
12:29PM	AstraZeneca Moves to NYSE as $50 Billion US Investment Plan Takes Focus (GuruFocus.com)
11:00AM	AZN Obesity Pipeline to Get a Boost From Deal With China's CSPC (Zacks)
07:00AM	AstraZeneca begins trading on the New York Stock Exchange (Business Wire)
02:46AM	AstraZeneca Shares to Start Trading in US After Listing Upgrade (Bloomberg)
Jan-30-26 12:28PM	Health Care Roundup: Market Talk (The Wall Street Journal)
11:11AM	Block quotes in PNR test (Test Provider for Finance)

AstraZeneca Plc is a global, science-led biopharmaceutical company focused on the discovery, development, and commercialization of prescription medicines. Its portfolio spans oncology, rare diseases, and biopharmaceuticals, including cardiovascular, renal & metabolism, and respiratory & immunology. The company was founded in 1913 and is headquartered in Cambridge, the United Kingdom.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

AZN

Astrazeneca plc

Upgrade your FINVIZ experience